Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 11/20 | 0.43 |
| ▸ | CTSS | P25774 | 4/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9303991 | 1.00 | CA1 (0.47) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL5709570 | 0.86 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL7872100 | 0.86 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL23749683 | 0.86 | CA1 (0.50) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL24387452 | 0.81 | CA1 (0.46) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL8972253 | 0.80 | CYP2D6 (0.63) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL5198000 | 0.80 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL25270811 | 0.80 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL17616112 | 0.80 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK | |
| SCHEMBL1372203 | 0.80 | CA1 (0.51) | CA1CA2CA7CYP2D6CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5321036-A | Treatment of diabetes, obesity and gastrointestinal disorders | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-06-14 | — | — | US | disclosed |